Mira Pharmaceuticals, Inc. Announces Positive Preclinical Results for Mira-55, a Non-Opioid Pain and Anxiety Treatment

Posted on March 23, 2026 at 11:50 pm (GMT+8)

NIL
Disclaimer:
This article is a summary interpretation of a regulatory filing and does not constitute investment advice. Investors should review the full filing and consult with a qualified financial advisor before making investment decisions.

View MIRA PHARMACEUTICALS, INC. Historical chart here

Energy Services of America Corporation Files Form 8-K with SEC – Company Details, Stock Information, and Filing Summary

The Crypto Company Enters Mutual Transfer and Release Agreement With Starchive.io, Inc. – March 2026 8-K Filing

Mira Pharmaceuticals, Inc. Announces Positive Preclinical Results for Mira-55, a Non-Opioid Pain and Anxiety Treatment

View MIRA PHARMACEUTICALS, INC. Historical chart here

Related Posts

Sprinklr Reports Q4 and Full Year Fiscal 2026 Results: $220.6M Revenue, 9% Growth, and Key Financial Highlights

Adicet Bio, Inc. 2025 Annual Report: Allogeneic Gamma Delta T Cell Therapy for Autoimmune Diseases and Cancer – Strategy, Risks, and Financial Overview

Kinetic Seas Incorporated Enters $148,500 Unsecured Promissory Note with Labrys Fund II, L.P. – 8-K Filing Details and XBRL Data